Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02439346
Other study ID # 17450
Secondary ID 2014-004810-27
Status Terminated
Phase Phase 1
First received May 7, 2015
Last updated March 6, 2018
Start date June 15, 2015
Est. completion date April 24, 2017

Study information

Verified date March 2018
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.


Description:

BAY 1143269 is a potent and selective, orally administered novel inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1). MKNK1 activity is essential for the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), which promotes the synthesis of oncogenic proteins, inhibits apoptosis, and helps tumor cells survive under stress. Increased p-EIF4E levels were found in tumor tissues from cancer patients. MKNK also functions as a mediator of pro-inflammatory cytokine production.

Established anti-mitotic drugs such as vinca alkaloids, taxanes, or epothilones activate the spindle assembly checkpoint (SAC), a key surveillance mechanism that monitors the attachment of spindle microtubules to the kinetochores of the chromosomes during pro-metaphase and halts the transitions to anaphase until all chromosomes are bi-oriented, fully attached, and correctly tensed at the metaphase plate. These antimitotic drugs destabilize or stabilize the spindle microtubules and cause mitotic arrest. Prolonged arrest in mitosis forces a cell either into a mitotic exit without cytokinesis or into a mitotic catastrophe leading to cell death. MKNK1 inhibitors allow cell apoptosis and increase tumor death. The combination of taxane and MKNK1 inhibitor can ultimately delay tumor progression and may provide a useful anticancer therapeutic approach.

This study will attempt to answer the following questions:

- What is the maximum tolerated dose (MTD) of BAY 1143269 when given alone or in combination with docetaxel?

- What is the safety profile and pharmacokinetics of BAY1143269 when given at the MTD?

- What are the adverse events of BAY 1161909 when given at different dose levels with docetaxel?


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date April 24, 2017
Est. primary completion date March 27, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female subjects aged > 18 years

- Subjects must have histologically or cytologically confirmed locally advanced or metastatic solid tumors and must be refractory to any standard therapy, or have no standard therapy available, or have actively refused any standard therapy or, in the investigator's opinion, experimental treatment in this study is clinically and ethically acceptable for the subject.

- Subjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1)

- Subjects must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Subjects must have a life expectancy of at least 12 weeks

- Subjects must have adequate bone marrow function as assessed by the following: hemoglobin >=9.0 g/dL or >=5.6 mmol/L, absolute neutrophil count (ANC) >=1.500/mm^3 or >=1.5 x 10^9/L (CTCAE Grade <=1), platelet count >= 100000/mm^3 or >=100 x 10^9/L

- Subjects must have adequate kidney function, as assessed by the estimated glomerular filtration rate (eGFR) >=60 mL/min per 1.73 m*2 [Common Terminology Criteria for Adverse Events(CTCAE Grade <=1)] calculated by the Modification of Diet in Renal Disease Study Group (MDRD) formula

- Subjects must have adequate liver function assessed by: total bilirubin <= 1.0 x upper limit of normal (ULN), aspartate aminotransferase (ALT) <= 3.0 x ULN (CTCAE Grade <=1) or, if receiving BAY1143269 in combination with IV docetaxel, AST and ALT <=1.5 x ULN if concomitant with alkaline phosphatase increase >2.5 x ULN

- Subjects must have adequate coagulation as assessed by: international normalized ratio (INR) or prothrombin time (PT) <=1.5 times ULN (CTCAE Grade <=1), partial thromboplastin time (PTT) <=1.5 x ULN (CTCAE Grade <=1)

- Women of reproductive potential must have a negative serum beta human chorionic gonadotropin (b-HCG) pregnancy test within 7 days before the first dose of study drug. Women of reproductive potential and men with female partners of childbearing potential must agree to consistently use highly effective contraception between signing the informed consent and 60 days after the last administration of study drug

Exclusion Criteria:

- Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis) or any previous cancer curatively treated <3 years before the first dose of study drug

- Subjects who have a history of, or current evidence of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE Grade >= 2 <4 weeks before the first dose of study drug.

- Subjects who have new or progressive brain or meningeal or spinal metastases

- Subjects who have a history of, or current evidence of uncontrolled cardiovascular disease or a left ventricular ejection fraction (LVEF) <50%

- Women who are pregnant or breast-feeding

- Subjects experiencing unresolved toxicity of previous antitumor therapy (excluding alopecia) which is CTCAE Grade >1 at screening

- Subjects who are current smokers or users of other tobacco products or have quit <90 days before first dose of study drug

- Subjects taking or likely to take strong and moderate CYP2D6 inhibitors, strong CYP1A1 inhibitors, and/or CYP1A1/CYP1A2 sensitive substrates or with narrow therapeutic index. Subjects receiving oral BAY1143269 and IV docetaxel must not take or be likely to take strong CYP3A1 inhibitors

- Subjects who have received systemic antitumor therapy within 4 weeks or radiotherapy to target lesions within 3 weeks before the first dose of study drug, which is longer

- Subjects who had received investigational drug treatment, including BAY1143269 and docetaxel, outside of this study within 4 weeks before the first dose of study drug, or for small molecules within the 5 half-lives of the agent before the first dose of study drug, whichever is longer

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BAY1143269 tablet
BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) of Oral BAY1143269 Alone and in Combination With Intravenous Docetaxel The MTD of oral BAY1143269 given alone was defined as the maximum dose at which the predicted incidence of dose-limiting toxicities (DLTs) during Cycle 1 is below 30 percent (%). Up to 2 years
Primary Maximum Observed Drug Concentration (Cmax) in Plasma After Single and Multiple Dose Administration of BAY1143269 Maximum observed concentration of BAY1143269 in plasma after single dose and multiple dose administration was measured. Cycle 1, 2 Day 1: Pre-dose to 24 hours post-dose
Primary Area Under the Concentration-time Curve From Time Zero to 24 Hours [AUC(0-24)] After Single and Multiple Dose Administration of BAY1143269 Area under the concentration-time curve from zero to 24 hours after single dose and multiple dose administration of BAY1143269 in plasma was measured. Cycle 1, 2 Day 1: Pre-dose to 24 hours post-dose
Secondary Tumor response Tumor response was assessed by Response Evaluation Criteria in Solid Tumors(RECIST V1.1). Evaluation of target lesions included CR(Disappearance of all target lesions),PR(at least a 30% decrease in sum of diameters of target lesions),PD:at least a 20% increase in sum of diameters of target lesions, taking smallest sum recorded as reference since treatment started or appearance of one or more new lesions) and Stable disease(SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD).Evaluation of non-target lesions included CR(disappearance of all non-target lesions and normalization of tumor marker level),Non-CR/PD(Persistence of 1 or more non target lesions and/or maintenance of tumor marker level above normal limits) and PD(Appearance of 1 or more new lesions and/or unequivocal progression of existing non target lesions). Baseline; end of Cycle 2
See also
  Status Clinical Trial Phase
Completed NCT02824042 - Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Phase 1
Completed NCT02253420 - COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients Phase 1
Completed NCT02357953 - Transpulmonary Thermodilution Using an Implented Central Venous Access Port N/A
Completed NCT02645357 - Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients N/A
Recruiting NCT04931329 - Onco-haematology Vigilance Card
Terminated NCT02138812 - Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Phase 1
Recruiting NCT05356182 - A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies N/A
Terminated NCT02368951 - Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) Phase 1
Not yet recruiting NCT05423808 - Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients. N/A
Recruiting NCT05385718 - Ezra Faster Scan Study
Completed NCT02457351 - Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study Phase 1
Completed NCT02906423 - Results From a Health System-wide Implementation of a Quality of Life Questionnaire N/A
Completed NCT01409135 - A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 Phase 1
Not yet recruiting NCT02327806 - The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance N/A
Completed NCT02639091 - Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Phase 1
Completed NCT02366949 - Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Phase 1
Not yet recruiting NCT06097533 - Improvement of Quality of Life by Cannabinoids in Oncologic Patients Phase 2/Phase 3
Completed NCT02427490 - A Problem-Solving Intervention for Family Caregivers in Palliative Oncology N/A
Recruiting NCT05359848 - A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy N/A